TABLE 2

Respiratory syncytial virus vaccines

Brand name (vaccine form)Approved agesaDoseEfficacy, %bSide-effect rates, %
Arexvy (inactivated protein subunit, adjuvanted)15≥ 75 years
60–74 years with high-risk factor		0.5 mLSeason 1: 94.1
Season 2: 84.6		Severe reactogenicity events 3.8 (vs 0.9 with placebo)
Pain 60.9
Fatigue 33.6
Myalgia 28.9
Headache 27.2
Abrysvo (inactivated protein subunit, nonadjuvanted)14,15≥ 75 years
60–74 years with high-risk factor
Pregnant at 32–36 weeks’ gestation		0.5 mLSeason 1: 88.9
Season 2: 78.6		Severe reactogenicity events 1.0% (vs 0.7% with placebo)
Pain 10.5
Fatigue 15.5
Myalgia 10.1
Headache 12.8
mResvia (inactivated messenger RNA encoding the respiratory syncytial virus F glycoprotein)13,16≥ 75 years
60–74 years with high-risk factor		0.5 mLSeason 1: 80.9
Season 2: 61.1		Severe reactogenicity events 6.1 (vs 4.0 with placebo)
Pain 55.9
Fatigue 30.8
Myalgia 25.6
Headache 26.7

  • ↵a This table does not include maternal indication data.

  • ↵b Efficacy in preventing symptomatic, laboratory-confirmed respiratory syncytial virus–associated lower respiratory tract disease with at least 3 lower respiratory signs.